ESMO Media Releases

Study using thymidylate synthase as a predictive and prospective biomarker. Report on a trial with a drug that targets the folate receptor.

The first direct comparison of treating non-squamous lung cancer with either pemetrexed or docetaxel in addition to cisplatin has shown that the two combinations achieve similar progression-free survival, although docetaxel was associated with more frequent adverse events.

One of the most exciting features of immune checkpoint inhibitors (ICIs) is that they provide impressive tumour responses in metastatic cancers of different histologies

Phase III trial indicates the drug is safe and well tolerated in advanced non-small cell lung cancer

Rolapitant reduces nausea and vomiting in patients receiving cisplatin-based chemotherapy

Presentations at ESMO 2014 examine the impact of in-utero exposure to chemotherapy and radiotherapy; the safety of lymph node biopsy in pregnancy; and the outcomes of unplanned pregnancy during cancer treatment

Fecal occult blood screening increases high-risk polyp detection by 89%. For high-risk patients, FOBT screening may be more efficient than colonoscopy.

Across Europe, more than 70% of young cancer specialists are showing signs of burnout, the largest survey of its kind has revealed

Canada and Europe sometimes years slower than USA in approving cancer drugs. Breast cancer patients in Eastern Europe have inadequate access to trastuzumab.

Result of a collaborative effort between ESMO and the European School of Oncology (ESO)

Lugano, Switzerland, 15 September 2014 – Poster and Poster Discussion abstracts to be presented at the ESMO 2014 Congress will be published online on Wednesday, 17 September 2014 at 12:00 (CEST) to give you a first glimpse of what you can expect from the European medical oncology Congress, under the leading theme Precision Medicine in Cancer Care.